Nasus Pharma Ltd. (NYSE AMERICAN: NSRX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT NASUS PHARMA LTD.

Nasus Pharma Ltd. (NYSE AMERICAN: NSRX)
Listen to this Section


$3.26
+0.0200 ( +0.62% ) 0.5K

Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma's intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma's proprietary powder-based intranasal ("PBI") technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity's rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.

Market Data


Open $3.26
Previous Close $3.24
Volume 0.5K
Market Cap $36.30M
Day Range $3.19 - $3.30
52 Week Range $1.98 - $9.99
Shares Outstanding 11.71M
Change % +0.62%
Net Change ▲ 0.0200
Insider Ownership N/A
Exchange NYSE AMERICAN
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Year2025
CountryIsrael
UnderwriterLaidlaw & Company (UK), Craft Capital Management, more

Insider Ownership Transactions

Total Amount Purchased: 15,000.00

Date Type Amount Purchased Purchaser
2026-04-01 Buy 15000.00 Teleman Dan Benjamin

SEC Filings


Form Type Description Pages Date
schedule Other 2 Apr 07, 2026
4 Insider transactions 1 Apr 01, 2026
3 Insider transactions 1 Mar 27, 2026
3 Insider transactions 1 Mar 27, 2026
3 Insider transactions 1 Mar 27, 2026
3 Insider transactions 1 Mar 27, 2026
3 Insider transactions 1 Mar 27, 2026
3 Insider transactions 1 Mar 27, 2026
3 Insider transactions 1 Mar 27, 2026
3 Insider transactions 1 Mar 27, 2026

Latest News


× Before browsing our site, please accept our cookies policy